Skip to main content
. 2020 Jan 9;15(7):1266–1273. doi: 10.4103/1673-5374.272616

Table 1.

Comparison of baseline data of acute cerebral infarction patients between the cattle encephalon glycoside and ignotin (CEGI) group and the placebo group

Baseline data CEGI group (n = 239) Placebo group (n = 80) Statistics P-value
Age (yr) 61.2±9.2 63.2±8.28 t=1.74 0.083
Height (cm) 166.3±6.94 165.1±7.11 Z=1.08 0.282
Weight (kg) 66.3±9.52 66.3±8.39 Z=0.222 0.824
Sex χ2=1.39 0.234
 Male 155 (64.9) 46 (57.5)
 Female 84 (35.1) 34 (42.5)
Respiratory rate (times/min) 18.9±1.49 18.8±1.57 Z=0.179 0.858
Body temperature (°C) 36.5±0.33 36.5±0.32 Z=0.304 0.761
Systolic blood pressure (mmHg) 146.5±20.8 147.4±23.1 Z=0.237 0.812
Diastolic blood pressure (mmHg) 86.7±13 84.7±12.2 Z=1.26 0.207
Time of progression (h) 22.5±13.8 25.1±14.5 Z=1.49 0.136
Allergic history χ2=0.316 0.854
 Yes 7 (2.93) 3 (3.75)
 No 220 (92.1) 72 (90.0)
 Unknown 12 (5.02) 5 (6.25)
Previous medical history χ2=0.009 0.926
 Yes 139 (58.2) 47 (58.8)
 No 100 (41.8) 33 (41.2)
Barthel Index scores 64.1±18.8 63.38±20.2 Z=0.117 0.907
National Institute of Health Stroke Scale scores 8.10±2.68 7.69±2.10 Z=1.07 0.286
Modified Rankin Scale scores 2.76±0.78 2.80±0.85 Z=0.219 0.827

Data are expressed as the mean ± SD except sex, allergic history, and previous medical history [n (%)]. The one-sided Cochran–Mantel– Haenszel (CMH) chi-squared test and independent t-test were used.